Company profile
SCYNEXIS, Inc.
NASDAQ: SCYX · Healthcare · Medical - Pharmaceuticals
#543 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
61CFH 56DQ 70GM 62SS 49
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), balance-sheet leverage · ↓ growth stability, Piotroski F
Methodology →Revenue TTM
$20.3M
Rev growth YoY (TTM)
+673.5%
Net income (FY)
-$8.6M
Employees
18
as of 2026-08-20
Market cap
$32.4M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$20.6M$20.6M2025
Net income-$8.6M-$8.6M2025
Operating income-$16.1M-$16.1M2025
Total assets$59.0M$59.0M2025
Liabilities$9.7M$9.7M2025
Equity$49.4M$49.4M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License and Service93%
Product7%
By geography
Not disclosed.
The read
What is SCYNEXIS, Inc.’s revenue?
SCYNEXIS, Inc. booked $20.6M in FY2025 revenue, growing 450% year over year — faster than 94% of Healthcare companies we track, at a -41.8% net margin.
Peers · Healthcare
SQZ Biotechnologies Company——Alector, Inc.40DMaxCyte, Inc.48DEvofem Biosciences, Inc.42DAcutus Medical, Inc.——Nutrition Management Services Company——Neighbors
Hudson →Key facts
CEODavid Angulo
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersJersey City, NJ
ExchangeNASDAQ: SCYX
Employees18
IPO date2014-05-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.